Cellestia Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Employees
  • 15

Employees

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $2.34M

  • Investors
  • 13

Cellestia General Information

Description

Developer of targeted therapeutics designed to treat multidrug-resistant cancers and autoimmune disorders. The company's technology utilizes a proprietary drug discovery platform to target gene transcription factors at the nuclear level, featuring an oral pan-NOTCH inhibitor, protein-protein interaction inhibition, and biomarker-driven patient selection, enabling healthcare providers to address unmet medical needs in patients with aggressive and hard-to-treat malignancies.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Technology Park Basel
  • Hochbergerstrasse 60C
  • 4057 Basel
  • Switzerland
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • Technology Park Basel
  • Hochbergerstrasse 60C
  • 4057 Basel
  • Switzerland

Cellestia Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cellestia Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
14. Grant 23-Jan-2024 $2.34M Completed Clinical Trials - Phase 2
13. Secondary Transaction - Private 28-Jun-2023 Completed Clinical Trials - Phase 2
12. Accelerator/Incubator Completed Clinical Trials - Phase 2
11. Later Stage VC (Series C) 17-Aug-2021 Completed Clinical Trials - Phase 2
10. Later Stage VC (Series B) 17-Dec-2019 Completed Clinical Trials - Phase 1
9. Grant 01-Jan-2019 Completed Clinical Trials - Phase 1
8. Early Stage VC (Series A) 20-Dec-2018 Completed Clinical Trials - Phase 1
7. Seed Round 10-Apr-2018 Completed Clinical Trials - Phase 1
6. Seed Round 28-Mar-2016 $32.1K Completed Startup
5. Grant $1.02M $32.1K Completed Startup
To view Cellestia’s complete valuation and funding history, request access »

Cellestia Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary
Ordinary
Ordinary
Ordinary 346,341 $6.65 $6.65 1x $6.65 7.09%
Ordinary 83,473 $6.04 $6.04 1x $6.04 1.71%
To view Cellestia’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Cellestia Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of targeted therapeutics designed to treat multidrug-resistant cancers and autoimmune disorders. The company's
Drug Discovery
Basel, Switzerland
15 As of 2024

Wilmington, DE
 

Cambridge, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Cellestia Competitors (5)

One of Cellestia’s 5 competitors is Ayala Pharmaceuticals, a Corporation company based in Wilmington, DE.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Ayala Pharmaceuticals Corporation Wilmington, DE
Artios Venture Capital-Backed Cambridge, United Kingdom
SpringWorks Therapeutics Formerly VC-backed Stamford, CT
Akamis Bio Venture Capital-Backed Abingdon, United Kingdom
ADC Therapeutics Formerly VC-backed Epalinges, Switzerland
You’re viewing 5 of 5 competitors. Get the full list »

Cellestia Patents

Cellestia Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4223292-A1 Pharmaceutical combinations for treating cancer Pending 07-Feb-2022
EP-4429661-A1 Pharmaceutical combinations for treating cancer Pending 08-Nov-2021
US-20250000870-A1 Pharmaceutical combinations for treating cancer Pending 08-Nov-2021
WO-2023079132-A1 Pharmaceutical combinations for treating cancer Inactive 08-Nov-2021
EP-4346816-A2 Compounds for use in a method for treating an autoimmune and inflammatory disease Active 02-Jun-2021 A61K31/44
To view Cellestia’s complete patent history, request access »

Cellestia Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cellestia Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds
Innosuisse Government
Bernina BioInvest Venture Capital Minority
Hemex (Healthcare Services) VC-Backed Company Minority
Invus (Private Equity) PE/Buyout Minority
SNGLR Capital Venture Capital Minority
You’re viewing 5 of 13 investors. Get the full list »

Cellestia Investments (1)

Cellestia’s most recent deal was a Joint Venture with Anciata Therapeutics for . The deal was made on 10-Apr-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Anciata Therapeutics 10-Apr-2025 Joint Venture Drug Discovery
To view Cellestia’s complete investments history, request access »

Cellestia FAQs

  • When was Cellestia founded?

    Cellestia was founded in 2014.

  • Where is Cellestia headquartered?

    Cellestia is headquartered in Basel, Switzerland.

  • What is the size of Cellestia?

    Cellestia has 15 total employees.

  • What industry is Cellestia in?

    Cellestia’s primary industry is Drug Discovery.

  • Is Cellestia a private or public company?

    Cellestia is a Private company.

  • What is Cellestia’s current revenue?

    The current revenue for Cellestia is .

  • How much funding has Cellestia raised over time?

    Cellestia has raised $50.8M.

  • Who are Cellestia’s investors?

    Innosuisse, Bernina BioInvest, Hemex (Healthcare Services), Invus (Private Equity), and SNGLR Capital are 5 of 13 investors who have invested in Cellestia.

  • Who are Cellestia’s competitors?

    Ayala Pharmaceuticals, Artios, SpringWorks Therapeutics, Akamis Bio, and ADC Therapeutics are competitors of Cellestia.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process